Lunai Bioworks (LNAI) Receivables (2012 - 2025)

Lunai Bioworks (LNAI) recorded quarterly Receivables of $1.1 million in Q1 2025, up 1.66% quarter-over-quarter from $1.1 million in Q4 2023.

Lunai Bioworks (LNAI) Receivables (2012 - 2025) Analysis & Trends

Lunai Bioworks' Receivables history runs 7 years deep, the most recent figure standing at $1.1 million for Q1 2025.

In Q1 2025, Receivables changed N/A year-over-year to $1.1 million; the TTM figure through Mar 2025 stood at $1.1 million (changed N/A YoY), while the FY2016 annual figure was $695418.0, down 53.17% from the prior year.
Receivables was $1.1 million for Q1 2025 at Lunai Bioworks, up from $1.1 million in the prior quarter.
In the past five years, Receivables ranged from a high of $1.1 million in Q1 2025 to a low of $1.0 million in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	13.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	2.00 Bn
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Lunai Bioworks	95.85 Mn	92.70 Mn	20,942.00	-

Download Data